Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
The effect of high-dose aprotinin treatment on hemostatic activation during cardiopulmonary bypass in pediatric patients having cardiac operations was investigated. Sixty patients weighing less than 10 kg undergoing cardiac operations for different types of congenital heart diseases were studied: 20 patients were treated with aprotinin 2 x 15,000 KIU/kg, 20 patients with 2 x 30,000 KIU/kg, and 20 patients without aprotinin treatment served as the control group. Different split products of fibrinogen and/or fibrin and the fibrinolytic activity on fibrin plates were measured to assess fibrinolytic activation. F1/F2 prothrombin fragments, thrombin-antithrombin III-complex, and fibrin monomers were measured to estimate thrombin activation. There was a significant dose-dependent reduction in fibrin-fibrinogen split product formation during cardiopulmonary bypass: In the high-dose aprotinin group the concentration of the split products at the end of bypass was 1.5 +/- 0.6 micrograms/ml, compared with 3.4 +/- 3.0 micrograms/ml in the low-dose aprotinin group and 6.7 +/- 3.5 micrograms/ml in the control group (p < 00.5). Fibrinolytic activation on fibrin plates was also significantly reduced by aprotinin. Fibrin monomer formation was significantly diminished at the end of cardiopulmonary bypass in the high-dose group: 9.2 +/- 5.2 micrograms/ml compared with 21.6 +/- 14 micrograms/ml in the control group (p < 00.5). Elastase in complex with alpha 1-protease inhibitor at the end of bypass was increased to the same amount in the three groups: 784 +/- 278 ng/mL (control group), 693 +/- 189 ng/ml (low-dose aprotinin), and 719 +/- 270 ng/mL (high dose aprotinin) (no significant difference). Blood loss 6 hours postoperatively was significantly (p < 00.5) less in the high-dose group (99 +/- 32 ml/m2) than in the control group (164 +/- 87 ml/m2; low-dose group: 160 +/- 106 ml/m2). These observations suggest an attenuation of hemostatic activation during cardiopulmonary bypass with less plasmin formation and, because of inhibition of contact activation, less thrombin generation with aprotinin treatment. Thus the thrombotic-thrombolytic equilibrium is kept more balanced after cardiopulmonary bypass. High-dose aprotinin treatment is recommended for pediatric patients undergoing cardiac operations.
Dietrich
W
W
Institute for Anesthesiology, German Heart Center, Munich.
Mössinger
H
H
Spannagl
M
M
Jochum
M
M
Wendt
P
P
Barankay
A
A
Meisner
H
H
Richter
J A
JA
D000990:Antithrombin III / Q000032:analysis / Q000187:drug effects; D007611:Aprotinin / Q000008:administration & dosage* / Q000097:blood; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass; D004305:Dose-Response Relationship, Drug; D005337:Fibrin / Q000032:analysis / Q000187:drug effects; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis / Q000187:drug effects; D005340:Fibrinogen / Q000032:analysis / Q000187:drug effects; D006488:Hemostasis, Surgical; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010447:Peptide Hydrolases / Q000032:analysis / Q000187:drug effects; D011516:Prothrombin / Q000032:analysis / Q000187:drug effects; D013997:Time Factors
D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D011516:Prothrombin; D005337:Fibrin; D005340:Fibrinogen; D007611:Aprotinin; D010447:Peptide Hydrolases